Summary. Forearm bone mineral content (BMC), as evaluated by photonabsorption densitometry, was measured in 28 cadaver kidney donor recipients who entered the study 8 weeks postoperatively and were followed up for 18 months. BMC decreased significantly (p<0.05) but marginally in placebo-treated patients (n=t4) (initial BMC 1.09±0.25g/cm; final BMC 1.05±0.24). Fourteen patients were prophylactically given 1,25(OH)2vitamin D 3 in a dose which avoided hypercalcemia and hypercalciuria (~0.25 gg/day); under 1,25(OH)z vitamin D 3 prophylaxis a significant decrease of forearm BMC was observed no longer (initial BMC 0.94_+.0.21 g/cm; final BMC 0.95 +_ 0.21), but the difference between placebo and 1,25(Ott)z vitamin D 3 narrowly missed statistical significance (p = 0.066).
Introduction
Osteopenia is a major complication of steroid therapy [1] . This may be particularly true after renal transplantation where steroids are part of the immunosuppressive regimen [2] [3] [4] [5] . Osteopenia represents one major risk thctor in the genesis of avascular necrosis of transplanted patients [6, 7] .
In animal experiments, 1,25(OH)2 vitamin D 3 has been shown to diminish the effect of immobilization on the skeleton [8] and prophylactic oral 1,25(OH)z vitamin D 3 was shown to be effective in preventing glucocorticoid osteopenia in rats [9] . In patients chronically treated with supraphysiologic doses of glucocorticoids Hahn et al. [10] [16] , several authors measured a variable but, on average, marked decrease of forearm mineral density in transplanted patients without vitamin D supplements, the average annual loss being 5-10% during the first year [2] .
The present prospective placebo-controlled trial was designed to examine whether prophylactic administration of 1,25(OH)2 vitamin D 3 after renal transplantation prevents bone mineral loss as measured by forearm radiodensitometry.
Patients and Methods

Patient Selection and Protocol
From July 1980 to September 1981, 61 patients were transplanted at the University of Heidelberg. All consecutive adult graft recipients entered the study 8 weeks after transplantation unless they had serum creatinine > 1.8 mg/dl, hypercalcemia, or systemic disease. The patients were randomly assigned to a treatment or a placebo group with the use of random numbers. A total of 38 patients entered the study. Ten patients (four in the treatment group, six in the placebo group) were withdrawn after randomization for the following reasons: two patients developed hypercalcemia and hyperparathyroidism; four rejected their graft and developed renal failure; four left Germany and were lost for follow-up.
Twenty-eight cadaver transplant recipients were followed up for 18 months (20 men, eight women, median age: 36 years; range: 17-53 years). Prior to transplantation, all patients had been on dialysis for a median of 42.1 months (range 1-120 months). None of the patients had symptomatic bone disease, elevated alkaline serum phosphatase, or hypercalcemia prior to transplantation. Vitamin D deficiency was excluded by normal 25(OH)vitamin D 3 levels at the time of entry into the study (182 ± 75 nmol/l).
1,25(OH)z Vitamin D 3 Therapy
The patients received either 0.25 gg 1,25-dihydroxy vitamin D 3 or placebo. The maximal dose was given that was tolerated without hypercalcemia (>2.75mmol/1) or hypercalciuria D 3 [20] were measured, and the bone mineral content determined.
Steroid Treatment
The patients received 1,000 mg methylprednisolone on the day of operation. In the absence of rejection crises, the steroid dose was tapered to a median of 16 mg/day 8 weeks postoperatively. Twelve months postoperatively (p.o.), the median maintenance steroid dose was 7.5mg methylprednisolone/day (range 4-12 mg). Eight patients were on an alternate-day schedule.
Acute rejection crises were treated with 1 g methylprednisolone i.v. for 1-3 days. The median cumulative steroid dose over 18 months was 12.932 mg range (7.276-20.684 mg) . The median number of rejection crises was 1.5 (range: 0-5) ; the median number of rejection crises in the two groups was not different.
Bone Densitometry
A bone mineral analyzer (Norland Instruments, Model 178) was used with a highly collimated beam of monoenergetic photons of a 200 mCi ~31I source. Uniformity of tissue absorption was achieved by applying a water-filled moulded rubber bag around the forearm. The distance olecranon-styloid process was measured. The point of transition between middle and distal third of the radius was chosen for measurement. For each determination eight measurements were made, and the results were averaged. Results were expressed as bone mineral content (BMC) in g/cm. In healthy probands, the CV for 12 replicate measurements at different days was 1.5%.
Statistics
Data are given as median and range. Initial and final BMC were compared with the sign test. In addition, relative slopes were analyzed after rank transformation using a Kruskat-Wallis test for two samples and 1 df
Results
At the beginning (2 months p.o.) and end (20 months p.o.) of the study, the two groups, i.e. placebo versus 1,25(OH)2 vitamin D3, were comparable with respect to serum creatinine, serum phosphorous, iPTH, and urinary cAMP. In the placebo group, median S-Crea was 1.5 mg/dl at 2 months and 20 months and S-Ca 2.4 and 2.5 mmol/1, respectively.
In the 1,25(OH)z vitamin D3-treated group, the respective values for S-Crea were 1.5 and 1.6mg/dl and for S-Ca 2.3 and 2.3. In both groups, median activities of alkaline serum phosphatase decreased (placebo from 164 to 127U/1; 1,25(OH)2 vitamin D 3 from 141 to 105). Median urinary Ca increased in both groups (placebo from 0.8 to 1.5mmol/l; 1,25(OH)z vitamin D 3 to 2.6). At 2 and 20 months, the median daily prednisolone dose was 12 mg (range: 1(~20) and 6 mg (range: [4] [5] [6] [7] [8] , respectively, in the placebo group and t 2 m g (range: 8-16) vs. 6 mg (range: [4] [5] [6] [7] [8] in the 1,25(OH)2 vitamin D 3 group.
BMC at various times after transplantation in placebo-and 1,25(OH) 2 vitamin D3-treated patients is given in Table 1 . There was a significant difference (p < 0.05) between initial and final BMC in the placebo group, but not in the 1,25(OH)z vitamin D3-treated group. After rank transformation, the difference of relative slopes for BMC between the two groups came close to, but did not reach, statistical significance (p = 0.066).
Discussion
Whereas previous authors [2, [13] [14] [15] [16] found a variabte but, on average, substantial decrease of forearm BMC in transplanted patients, such decrease was marginal, although statistically significant, in the present study. The greater change of BMC in previous studies may have been due to several factors, e.g., higher steroid dosage, severity of pre-existent hyperparathyroidism, inclusion of patients with impaired graft function, age, etc. Steroid dosage is presumably the most important factor to explain the above differences. A dose-dependent effect of steroids on calcium metabolism is suggested by the failure to observe changes of intestinal calcium absorption at less than 15 mg prednisolone/day [20] , while such decrease was readily demonstrable at high steroid doses [21] . Following the suggestions of McGeown [22] steroid doses have been reduced considerably in recent years and have even been further reduced since completion of the present study.
We found only a marginal, but statistically significant, decrease of BMC in placebo-treated patients. The limited magnitude of decrease is not due to the insensitivity of the photonabsorption technique. In particular, the error of replicate measurements was quite small (CV 1.5%).
Cortical bone makes an overriding contribution to BMC at the site of our forearm measurements. However, it is spongy bone as the metabolically most active osseous tissue with the highest turnover rate which decreases most after steroid administration [24, 25] . Furthermore, spongy bone is of special importance in the genesis of avascular bone necrosis [26] . Loss of spongy bone may not be optimally reflected by measurements assessing preferentially cortical bone in patients with renal disease [16] or other disease states [27] . In transplanted patients, prophylactic administration of t,25(Ott)2 vitamin D 3 tended to reduce bone loss when compared with placebo, although the difference between placebo and t,25(OH) 2 vitamin D 3 did not quite reach statistical significance. This finding is in general agreement with previous experimental [9] and clinical [10] studies in non-renal animals or subjects. However, given the small magnitude of forearm BMC change in placebo-treated controls, this finding is of questionable biologic significance. Consequently, on the basis of these results it would not appear justified to recommend prophylactic administration of 1,25(OH)2 vitamin D 3 in transplant recipients who have normal renal function and are on low maintenance doses of steroids. However, a significant reduction in the incidence of osteonecrosis in recipients of renal homografts was noted recently, when a vitamin D 2 supplement was administered prophylactically [28] . This clinical observation validates the rationale underlying our study.
The tendency to use lower steroid doses is presumably responsible for the diminishing incidence of avascular femoral head necrosis. Formerly, it tended to be above 10% [6] but has diminished ever since. In 339 patients consecutively transplanted in our center, the incidence of aseptic necrosis was 4.12% [7] , and an incidence below 1% was reported when still lower doses of steroids were chosen [20] . In the future, steroidfree immunosuppressive regimens may hopefully largely eliminate the problem in transplanted patients. However, the need to reduce secondary hyperparathyroidism and the attended risk of osteopenia will persist for steroid-treated non-renal patients [28] .
